Biogen's Empaveli sustains proteinuria reduction, stabilizes kidney function over 76 weeks

• Biogen will present long-term Phase 3 EMPAVELI results at ASN Kidney Week in Denver on October 22-25, 2026.
• The results show sustained reductions in urinary protein loss with continued kidney function stabilization over 76 weeks in C3G and primary IC-MPGN.
• The findings show a consistent long-term safety profile, supporting EMPAVELI’s recently expanded U.S. indication to reduce kidney function loss.
• Additional presentations will cover investigational felzartamab, currently in three Phase 3 trials targeting immune-mediated kidney diseases.
• Results from felzartamab’s TRANSCEND trial in antibody-mediated rejection among adult kidney transplant recipients are expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190730OMX_____CNEWS_EN_GNW9847675_en) on October 19, 2026, and is solely responsible for the information contained therein.